Oncology Letters · 2010 · 50 citations · 33 references
MedicineOncologySurgeryChemotherapyGastrointestinal OncologySurgical OncologyGastric CancerGastrointestinal Cancer SurgeryPalliative Cancer SurgeryPalliative ChemotherapyPalliative Oncologic SurgeryPalliative Surgery5-Fluorouracil TherapyComparative Cancer IncidenceGastric Cancer RadiotherapyGastric Cancer Systemic TherapyGastrointestinal Oncologic SurgeryOncologic Gastrointestinal SurgeryPalliative Chemotherapy AdministrationPalliative Therapy
Gastric cancer is one of the most frequently occurring cancers in China, with an estimated 380,000 new cases each year, accounting for more than 40% of the worldwide annual cancer incidence. There is geographical clustering of the distribution of gastric cancer in China, with most of the high-risk areas being rural. D2 resection is the standard lymphadenectomy for curative resection in China, but more extensive lymphadenectomy is conducted for selected patients. Perioperative chemotherapy, postoperative chemotherapy or chemoradiotherapy can be combined with surgery. It remains uncertain which option is best, but if surgery is insufficient, adjuvant chemoradiotherapy is recommended. In the palliative setting, although there is no standard first-line chemotherapy, regimens based on taxane, oxaliplatin or capecitabine, or the epirubicin, cisplatin, 5-fluorouracil regimen and its modifications are the most common options selected by Chinese oncologists. Several studies to evaluate target therapy are ongoing, but it is too early to draw any conclusions. However, the development of target therapy is likely to become a milestone in the treatment of gastric cancer.
33
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine · 2007 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +11
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
David Cunningham, Naureen Starling, Sheela Rao et al. · New England Journal of Medicine · 2008 · 2.3K citations
Medicine, Oncology, Pharmacology +12